TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk

- Anti-tumour necrosis factor (TNF) therapy is associated with an increased risk of infection. There are sparse data and no evidence-based guidelines on how to deal with this problem in daily practice. However, recommendations can be made based on theoretical considerations and by extrapolating from recommendations for other types of immunodeficiency.

- Before starting anti-TNF therapy, screening for tuberculosis and other possible infections is indicated. During therapy, alertness is required to the increased risk of infection, infections with a more serious clinical course or unusual manifestations and opportunistic infections.

- Flu vaccination during anti-TNF therapy is indicated. Travel vaccinations with live microbial inocula should not be given.

Ned Tijdschr Geneeskd. 2007;151:588-93